Cargando…

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer

BACKGROUND: Several prognostic signatures for early oestrogen receptor-positive (ER+) breast cancer have been established with a 10-year follow-up. We tested the hypothesis that signatures optimised for 0–5-year and 5–10-year follow-up separately are more prognostic than a single signature optimised...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buus, Richard, Yeo, Belinda, Brentnall, Adam R., Klintman, Marie, Cheang, Maggie Chon U., Khabra, Komel, Sestak, Ivana, Gao, Qiong, Cuzick, Jack, Dowsett, Mitch
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122470/ https://www.ncbi.nlm.nih.gov/pubmed/30180877 http://dx.doi.org/10.1186/s13058-018-1040-9

Ejemplares similares

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
por: Buus, Richard, et al.
Publicado: (2021)

Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
por: Sestak, Ivana, et al.
Publicado: (2018)

Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors
por: Sestak, Ivana, et al.
Publicado: (2016)

Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial
por: Hale, Michael J., et al.
Publicado: (2020)

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
por: Buus, Richard, et al.
Publicado: (2016)

Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study
por: Buus, Richard, et al.
Publicado: (2021)

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer
por: Bergamino, Milana A., et al.
Publicado: (2022)

Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers
por: Schuster, Eugene F., et al.
Publicado: (2023)

Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer
por: Sestak, Ivana, et al.
Publicado: (2013)

SNPs for breast cancer risk assessment
por: Cuzick, Jack, et al.
Publicado: (2017)

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
por: Dowsett, Mitch, et al.
Publicado: (2018)

Markers for the identification of late breast cancer recurrence
por: Sestak, Ivana, et al.
Publicado: (2015)

Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER(+)/HER2(−) Breast Cancer
por: Dowsett, Mitch, et al.
Publicado: (2022)

Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer
por: Richman, Juliet, et al.
Publicado: (2020)

Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial
por: Cuzick, Jack, et al.
Publicado: (2020)

Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials
por: Cuzick, Jack, et al.
Publicado: (2017)

Genomic Instability and TP53 Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment
por: Schuster, Eugene F., et al.
Publicado: (2019)

Impact of preventive therapy on the risk of breast cancer among women with benign breast disease
por: Cuzick, Jack, et al.
Publicado: (2015)

Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients
por: Gao, Qiong, et al.
Publicado: (2019)

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
por: Esserman, Laura J, et al.
Publicado: (2005)

Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas
por: López-Knowles, Elena, et al.
Publicado: (2016)

Use of the concordance index for predictors of censored survival data
por: Brentnall, Adam R, et al.
Publicado: (2016)

Risk Models for Breast Cancer and Their Validation
por: Brentnall, Adam R., et al.
Publicado: (2020)

Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I)
por: Smith, Samuel George, et al.
Publicado: (2017)

Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors
por: Thanopoulou, Eirini, et al.
Publicado: (2014)

Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer
por: Haynes, Ben P., et al.
Publicado: (2021)

Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses
por: Poudel, Pawan, et al.
Publicado: (2019)

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy
por: Evans, A H, et al.
Publicado: (2010)

Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study
por: Lopez-Knowles, Elena, et al.
Publicado: (2022)

Estimating efficacy in trials with selective crossover
por: Brentnall, Adam R., et al.
Publicado: (2017)

Hormonal treatments in metastatic endometrial stromal sarcomas: the 10-year experience of the sarcoma unit of Royal Marsden Hospital
por: Thanopoulou, Eirini, et al.
Publicado: (2015)

Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia
por: Sestak, Ivana, et al.
Publicado: (2019)

Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial
por: Sestak, Ivana, et al.
Publicado: (2021)

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial
por: Cuzick, Jack, et al.
Publicado: (2015)

Identifying Biomarkers to Pair with Targeting Treatments within Triple Negative Breast Cancer for Improved Patient Stratification
por: Tovey, Holly, et al.
Publicado: (2019)

Pazopanib-Induced Alopecia, an Underestimated Toxicity?
por: Biondo, Andrea, et al.
Publicado: (2015)

Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer
por: Abubakar, Mustapha, et al.
Publicado: (2019)

The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies
por: Smith, Samuel G., et al.
Publicado: (2021)

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data
por: Cuzick, Jack, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_nh5ucspc1b3rgp75ir08f1qa2i